Navigation Links
Glycos Biotechnologies, Inc. Selected to Present at Alternative Energy Innovations 2009
Date:11/13/2009

Executive Chairman to Discuss Alternative Approach to Biofuel and Chemical Production

(PRWEB) November 13, 2009 -- Glycos Biotechnologies, Inc. (GlycosBio), a metabolic engineering innovator in biologically converting non-sugar feedstocks into next generation bioproducts, today announced Rich Cilento, Executive Chairman, will be a presenter at Alternative Energy Innovations 2009 on November 17th in Redwood City, CA.

With a mission to find a better way to create biofuels and chemicals, GlycosBio has uniquely discovered a number of microorganisms that can biologically convert by-products including glycerol and free fatty acids into higher-value green chemicals. By not following the typical sugars-based fermentation research, GlycosBio has created a proprietary technology that provides the industry with an alternative approach to traditional corn or sugar-based biofuel and chemical production.

In his presentation, Cilento will discuss the industry’s need to integrate microbe and fermentation technologies into their manufacturing plans. He will provide an overview of GlycosBio’s technology and how biofuel, oleochemical, palm oil and petrochemical producers can protect themselves from the commodity risk that a single feedstock business model brings; rapidly implement a biorefinery based on their existing plant and equipment; create greater yields and increase product values.

What:    “GlycosBio Business and Technology Overview”

Who:   Rich Cilento, Executive Chairman, GlycosBio

Where:   Alternative Energy Innovations: Sofitel San Francisco Bay, Redwood City, CA

When:   Biofuels Track: Tuesday, November 17 - 11:25am and 12:10pm

About Rich Cilento
Rich Cilento has extensive leadership and technical experience with energy, biotechnology, and information technology companies. He received national business honors in 2006, winning the Ernst and Young Entrepreneur of the Year Award for Energy Technology. Cilento is currently serving as Executive Chairman of DFJ Mercury portfolio company GlycosBio. Previously, he was the Founder, President and CEO of FuelQuest, Inc. (acquired by Saracen Energy), a provider of on-demand supply chain management and tax automation software and services for suppliers, distributors, fuel buyers and traders in Global Downstream Energy.

Cilento began his career at NASA where he was a space shuttle flight controller. He and his flight control team had responsibility for redesigning NASA’s Mission Control Center and implementing NASA’s Software Management Plan.

Cilento holds a BS in Aeronautical and Astronomical Engineering from the University of Illinois, an MBA from the University of Houston and serves as an advisor to a number of small businesses in Texas.

About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (GlycosBio) is pioneering the metabolic engineering of microbial strains to consume multiple non sugar-based, low value feedstocks for the production of sustainable chemical intermediates and advanced ethanol. By creating differentiated bioprocesses, GlycosBio’s bioconversion technology can lower costs, provide a non food energy balance and price stability to the chemical and biofuel industries. GlycosBio is a Houston-based industrial biotechnology company started with technology initially developed at Rice University. For more information, visit www.glycosbio.com.

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3192574.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
2. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
3. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
4. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
5. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
6. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
7. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
8. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
9. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
10. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
11. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... its new stem cell treatment clinic in Quito, Ecuador. The new facility will ... trauma applications to patients from around the world. , The new GSCG ...
(Date:2/10/2016)... -- NX Prenatal Inc., a US based molecular ... early warning of adverse pregnancy outcomes, announced today ... Dr. Thomas McElrath of Brigham & ... (SMFM) annual meeting held in Atlanta ... presentation reported initial positive top-line results regarding the ...
(Date:2/10/2016)... Feb. 10, 2016  Allergan plc (NYSE: AGN ... Brent Saunders , Allergan,s CEO and President, will ... chat session at the RBC Capital Markets Healthcare Conference ... at The New York Palace Hotel in ... webcast live and can be accessed on Allergan,s Investor ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech ... SPIE Photonics West conference in San Francisco’s Moscone Center from February 16-18, 2016, ... venue. , These latest InGaAs PIN diode standard packages feature a TO-46 metal ...
Breaking Biology Technology:
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
Breaking Biology News(10 mins):